Spyre Therapeutics, Inc. (SYRE) Earnings Call Transcript & Summary

Good morning and welcome to the 2020 Annual Meeting of Stockholders of Aeglea BioTherapeutics. This meeting is being held in a virtual format due to the COVID-19 pandemic. Due to the nature of the virtual format, we may experience technical difficulties, and we will address any that come up as best as we can. Our host for today's call is Aeglea's President and Chief Executive Officer, Anthony Quinn. [Operator Instructions] I would now turn the call over to your host, Dr. Quinn. You may begin.

Thank you, operator. Good morning, everyone. It's a pleasure to welcome you to our Annual Meeting of Stockholders. The meeting is now called to order. I'd like to introduce the following members of the Board of Directors who are with us on the phone this morning: Russell Cox; Armen Shanafelt; Suzanne Bruhn; Sandy Mahatme; Ivana Liebisch; and Bryan Lawlis. I would also like to introduce our Chief Financial Officer, Charles York, who is with us this morning. Natalie Hairston from American Election Services, LLC will be acting as inspector of elections for this meeting, and I will serve as Chairman. Also want to introduce Robert Freedman of Fenwick & West LLP, our legal counsel who will act as secretary of the meeting and keep the minutes; and John Cummins of PricewaterCoopers LLP (sic) [ PricewaterhouseCoopers LLP ], our independent registered public accountants. We will now conduct the formal business matters of the meeting. April 13, 2020, was fixed by the Board of Directors as the record date for the proposals to be voted on at this meeting. Only holders of the company's common stock as of the close of business on the record date are entitled to receive notice of and to vote at this meeting. I present to this meeting an affidavit of Broadridge Financial Solutions attesting that a notice of meeting together with the proxy statement and proxy were mailed on or about April 23, 2020, to each holder of the company's common stock as of the close of business on the record date. The affidavit of mailing of the notice will be attached to the minutes of this meeting. A certified list of the holders of the issued and outstanding shares of common stock of the company as of the close of business on the record date is available by clicking the registered shareholders list link at the bottom of your screen. This list will be available for inspection during this meeting by any stockholder and will be filed with the records of the company. Broadridge Financial Solutions has examined the proxies received and reports that 29,147,461 shares or 87% of the total shares of common stock of Aeglea BioTherapeutics entitled to vote are represented by proxies or in person at this meeting. A majority of the votes entitled to be cast are represented at this meeting either in person or by proxy. A quorum is therefore present, and the meeting may now proceed. I will now review the agenda and voting procedures. We have 2 proposals on which the stockholders will be voting. Proposal #1 is the election of 2 Class I directors, each to serve a 3-year term, which will expire at the 2023 Annual Meeting of Stockholders. And proposal #2 is the ratification of the appointment of our independent registered public accounting firm. If you have previously returned a proxy or voted by phone or through the Internet and do not wish to revoke your proxy or change your vote, then you do not need to vote at this meeting. Your vote has already been included in the proxy count. If you did not return a proxy or wish to change your vote, you may do so by clicking Vote Here at the bottom right-hand corner of the screen. We will give you time to submit your ballots if necessary once we open the polls shortly. So proposal #1 is the nomination and election of 2 Class I directors. The Board of Directors has nominated each of Sandy Mahatme and Suzanne Bruhn to be elected as directors of the company for the next 3 years and until his or her successor is duly elected and qualified. Our bylaws require that a stockholder provide advanced notice of their intent to nominate persons as directors. No such notice was received. So accordingly, I declare the nominations for directors closed. Proposal #2 is to ratify the appointment of PricewaterhouseCooper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. Because no further business is scheduled to come before the stockholders, it is now approximately 9:06 a.m. Central time on June 8, 2020, and the polls are now open. If you did not return a proxy or wish to change your vote, you may do so by clicking Vote Here at the bottom right corner of your screen. [Voting]

It is now approximately 9:07 a.m. Central time on June 8, 2020, and I declare the polls for each matter voted upon at this meeting closed. The vote required for proposal #1 to elect the Class I directors, is the plurality of the votes cast, which means that the 2 individuals nominated for election to the Board of Directors at the meeting receiving the most affirmative for votes of the shares present or represented at this meeting will be elected. Each of the nominees have been elected. Sandy Mahatme and Suzanne Bruhn are the 2 individuals who received the most votes of shares present and entitled to vote. The vote required to approve proposal #2 to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting from for the fiscal year ending December 31, 2020, is an affirmative for vote of the majority of the shares represented -- present or represented at this meeting. This concludes the business portion of the meeting. There being no other business to conduct, I hereby declare the business portion of the meeting adjourned. There being no further business or questions, I'd like to thank you all very much for attending our Annual Meeting of Stockholders, and I hereby declare the meeting adjourned. Ladies and gentlemen, this concludes the 2020 Annual Meeting of Stockholders of Aeglea BioTherapeutics. You may now disconnect.

Ladies and gentlemen, thank you for participating, and you may now disconnect. Everyone, have a great day.